Actively Recruiting
Safety, Tolerability, and Effects of Inhaled LTI-03 Compared to Placebo in Adults With Idiopathic Pulmonary Fibrosis
Led by Rein Therapeutics · Updated on 2026-11-03
120
Participants Needed
48
Research Sites
13 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying LTI-03, an experimental inhaled medication, for the treatment of Idiopathic Pulmonary Fibrosis IPF, a progressive and fatal lung disease that causes scarring and loss of lung function. The study aims to assess the safety, side effects, and potential benefits of LTI-03 in improving lung scarring and symptoms in patients diagnosed with IPF within the last five years. Participants on stable doses of certain approved IPF medications may join. The study is a Phase 2, randomized, double-blind, placebo-controlled trial comparing LTI-03 to a placebo. Participants will inhale LTI-03 or placebo capsules twice daily using a dry powder inhaler. The trial includes a 28-day screening period, a 24-week treatment period, and a 4-week follow-up. Lung scans will be done at the start and end of treatment, with several clinic visits throughout the study. Participants will attend up to nine clinic visits where lung function tests, blood samples for safety and disease markers, and questionnaires about IPF symptoms will be conducted. Safety will be monitored through physical exams, vital signs, heart tests, and tracking side effects and medication changes. The main outcome will measure safety by recording treatment-related side effects over 24 weeks, while lung function and lung scarring changes will also be evaluated.
CONDITIONS
Brief Title
A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis
Research Team
S
Steven A. Shoemaker, MD
S
Shawna H. Evans
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here